| Patents for C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587) |
|---|
| 06/07/2006 | CN1784397A Methyl indoles and methyl pyrrolopyridines as alph-1 adrenergic agonists |
| 06/07/2006 | CN1784396A P38 inhibitors and methods of use thereof |
| 06/07/2006 | CN1784391A Quinazolines useful as modulators of ion channels |
| 06/07/2006 | CN1784387A Benzimidazole derivatives |
| 06/07/2006 | CN1784235A Fortifier |
| 06/07/2006 | CN1258532C Compound of poly-amide macrocyclic polyamine and its preparation process and application |
| 06/06/2006 | US7057046 Lactam glycogen phosphorylase inhibitors and method of use |
| 06/06/2006 | US7056944 Pyrazole compositions useful as inhibitors of erk |
| 06/06/2006 | US7056943 Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| 06/06/2006 | US7056941 for efficient control of animal pests from the class of insects, arachnids and nematodes, for controlling broad spectrum of phytopathogenic fungi, in particular from the class of the Ascomycetes, Deuteromycetes, Phycomycetes and Basidiomycetes |
| 06/06/2006 | US7056937 Sulfonylquinoxalone derivatives as bradykinin antagonists |
| 06/06/2006 | US7056927 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 06/06/2006 | US7056922 Acylamino cyclopropane derivatives |
| 06/06/2006 | US7056921 Substituted chroman derivatives |
| 06/06/2006 | US7056918 Benzimidazole anti-inflammatory compounds |
| 06/06/2006 | US7056915 Compounds useful as reversible inhibitors of cysteine proteases |
| 06/06/2006 | US7056911 for example, N-[(2,4-diaminopteridin-6-yl)methyl]-9,10-dihydrodibenz[b,f]azepine; may be useful for treatment or prophylaxis of diseases associated with parasitic infection such as pneumocystis pneumonia, toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria |
| 06/06/2006 | US7056907 Mandelic acid derivatives and their use as thrombin inhibitors |
| 06/06/2006 | US7056354 produces powerful, particularly bright and chromatic color, particularly red shades that are free of or contain very little blue or yellow; resistance to light, bad weather, washing, permanent-waving, perspiration and friction |
| 06/06/2006 | CA2213526C Stabilizer mixtures |
| 06/06/2006 | CA2199468C 1,2,3,4-tetrahydroquinoxalinedione derivative |
| 06/06/2006 | CA2158973C 1,5-benzodiazepine derivatives having cck antagonistic or agonistic activity |
| 06/01/2006 | WO2006058012A2 Gonadotropin releasing hormone receptor antagonists |
| 06/01/2006 | WO2006057945A2 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| 06/01/2006 | WO2006057922A2 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 06/01/2006 | WO2006057354A1 Processes for production of indole compounds |
| 06/01/2006 | WO2006056695A1 Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof |
| 06/01/2006 | WO2006041830A3 Cgrp receptor antagonists |
| 06/01/2006 | WO2006028957A8 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| 06/01/2006 | WO2005061467A3 Piperazine derivatives as bradykinin antagonists |
| 06/01/2006 | WO2005034940A8 Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological, inflammatory, neuronal and other diseases |
| 06/01/2006 | WO2004080407A3 New serotonin modulating compounds and uses therefor |
| 06/01/2006 | US20060116516 2-[[4-[[[4-(Aminosulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-4-methyl-5-thiazolecarboxylic acid, ethyl ester; 4-Methyl-2-[[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-5-thiazolecarboxylic acid, ethyl ester; Antiinflammatory agents; rheumatic diseases |
| 06/01/2006 | US20060116515 such as [[3-(Benzo[1,3]dioxol-5-ylmethyl-methyl-amino)-propyl]-(3-imidazol-1-yl-[1,2,4]thiadiazol-5-yl)-amino]-acetic acid ethyl ester, used as antiinflammatory and anticarcinogenic agents, or for the treatment of vision defects, metabolic, nervous system and respiratory system disorders |
| 06/01/2006 | US20060116416 e.g. [5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yloxy]-acetic acid; peroxisome proliferator activated receptor agonist; anticoagulant, antidiabetic agent; obesity, hyperlipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, diabetic neuropathy, atherosclerosis, eczema, psoriasis |
| 06/01/2006 | US20060116402 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library |
| 06/01/2006 | US20060116399 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 06/01/2006 | US20060116394 Fab I inhibitors |
| 06/01/2006 | US20060116390 Hepatitis c virus inhibitors |
| 06/01/2006 | US20060116388 CXCR3 antagonists |
| 06/01/2006 | US20060116385 Novel compounds having selective inhibiting effect at gsk3 |
| 06/01/2006 | US20060116384 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| 06/01/2006 | US20060116383 Integrin antagonists useful as anticancer agents |
| 06/01/2006 | US20060116380 Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| 06/01/2006 | US20060116379 Compounds exhibiting type X sPLA2 inhibiting effect |
| 06/01/2006 | US20060116376 Therapy of central nervous disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, anxiety, depression, and schizophrenia and fibromyalgia |
| 06/01/2006 | US20060116366 Spirocyclic ureas, compositions containing such compounds and methods of use |
| 06/01/2006 | US20060116365 Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone |
| 06/01/2006 | US20060116362 Nobel compounds having selective inhibiting effect at gsk3 |
| 06/01/2006 | US20060116357 Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate |
| 06/01/2006 | US20060116326 Benzothiophene compounds having antiinfective activity |
| 06/01/2006 | US20060115871 Protein interaction reporter agents and methods for using same |
| 06/01/2006 | US20060115848 Nucleic acid end-labeling reagents |
| 06/01/2006 | US20060115815 Method and compositions for identifying anti-hiv therapeutic compounds |
| 06/01/2006 | US20060113530 Multifunctional linker molecules for tuning electronic charge transport through organic-inorganic composite structures and uses thereof |
| 06/01/2006 | CA2587853A1 Gonadotropin releasing hormone receptor antagonists |
| 06/01/2006 | CA2585990A1 Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof |
| 05/31/2006 | EP1661569A1 Compounds effecting glucokinase |
| 05/31/2006 | EP1661568A1 Compounds effecting Glucokinase |
| 05/31/2006 | EP1661567A1 Compounds effecting Glucokinase |
| 05/31/2006 | EP1661563A1 Compound effecting Glucokinase |
| 05/31/2006 | EP1660487A1 Pyrrole compositions useful as inhibitors of c-met |
| 05/31/2006 | EP1660485A1 Improved process for preparing alpha-polymorphic eletriptan hydrobromide |
| 05/31/2006 | EP1660484A1 Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists |
| 05/31/2006 | EP1660460A1 Quinoxaline derivatives as neutrophil elastase inhibitors and their use |
| 05/31/2006 | EP1660458A1 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| 05/31/2006 | EP1660456A2 Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
| 05/31/2006 | EP1660454A1 Azacyclic compounds as inhibitors of sensory neurone specific channels |
| 05/31/2006 | EP1660447A1 Cyclic amine base-1 inhibitors having a heterocyclic substituent |
| 05/31/2006 | EP1660444A2 Metal complexes of n-heterocyclic carbenes as radiopharmaceuticals and antibiotics |
| 05/31/2006 | EP1660443A2 Cyclic amine bace-1 inhibitors having a benzamide substituent |
| 05/31/2006 | EP1660427A1 Substituted arylalkanoic acid derivative and use thereof |
| 05/31/2006 | EP1660092A2 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| 05/31/2006 | EP1660080A1 Furanone derivatives |
| 05/31/2006 | EP1527052B1 3-heterocyclyl substituted benzoic acid derivatives |
| 05/31/2006 | EP1345922B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1318997B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1317449B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1317444B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | CN1780822A Use of derivatives of 2, 4-dihydro- 1,2,4 triazole-3-thione as inhibitors of the enzyme myeloperoxidase (MPO) |
| 05/31/2006 | CN1780819A 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzoazepine derivative or salt of the same |
| 05/31/2006 | CN1780621A Sulfonamide derivatives as gamma secretase inhibitors. |
| 05/31/2006 | CN1780617A Imidazolin-2-ylaminophenyl amides as IP antagonists. |
| 05/31/2006 | CN1257902C Method for producing cilostazol |
| 05/31/2006 | CN1257894C Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 05/31/2006 | CN1257892C New indole derivatives with 5-HT6 receptor affinity |
| 05/31/2006 | CN1257891C Nitrogenous five-membered ring compounds |
| 05/31/2006 | CN1257886C Dehydroamino acids compounds |
| 05/30/2006 | US7053215 For therapy of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes |
| 05/30/2006 | US7053114 A modulator controls the activity of protein kinases, tyrosine kinase; enzyme inhibitors; nontoxic, solubility, formulability, bioavailability; cancer, diabetes, hepatic cirrhosis, atherosclerosis, angiogenesis, autoimmune disease and renal disease |
| 05/30/2006 | US7053113 Mannich base prodrugs of 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives |
| 05/30/2006 | US7053110 Dietetics; osteoporosis; muscular disorders |
| 05/30/2006 | US7053107 Antiproliferative agents, angiogenesis inhibitors for treating cancer, eye disorders, diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis; N-Cyclopropyl-2-{3-[(E)-2-(4-methyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-benzamide |
| 05/30/2006 | US7053105 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| 05/30/2006 | US7053101 Orphan opioid receptor (orl-1) ligands; anxiety, depression, neuropathic and acute pain, migraines, asthma, improved cognition |
| 05/30/2006 | US7053089 Such as 4-((methyl-pyrimidin-2-ylamino)-methyl)-piperidine-1-carboxylic acid benzyl ester; useful for pain relief; treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, and stroke; N-methyl-D-aspartate (NMDA) |
| 05/30/2006 | US7053088 Vanilloid receptor ligands and their use in treatments |
| 05/30/2006 | US7053086 For cancer therapy |
| 05/30/2006 | US7053081 Cyclic malonamides as inhibitors of A-β protein production |
| 05/30/2006 | CA2398159C Sulphonylaminocarbonyltriazolinones having substitutents bonded via oxygen |